Clinical Trials Directory

Trials / Unknown

UnknownNCT06277986

Early Diagnosis of Gastric Cancer Cachexia

Clinical Value of Tumor Cell-derived Exosomal miRNA in Early Diagnosis of Gastric Cancer Cachexia

Status
Unknown
Phase
Study type
Observational
Enrollment
150 (estimated)
Sponsor
Xijing Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Gastric cancer is one of the most common malignancies, the morbidity and mortality of which are among the highest. In cancer patients, the incidence of cachexia is very high, and even 80% of patients will eventually develop into cachexia. However, once gastric cancer patients develop cachexia, patients are unlikely to obtain clinically significant benefits from conventional treatment. Therefore, it is important to find biomarkers for early detection of cachexia. The investigators carried out a plasma-derived exosomal microRNA(miRNA) study for early diagnosis of cachexia in gastric cancer, and the development of early diagnosis kits for gastric cancer cachexia.

Detailed description

Gastric cancer is one of the most common malignancies, the morbidity and mortality of which are among the highest. In gastric cancer patients, the incidence of cachexia is very high, and even 80% of patients will eventually develop into cachexia. However, once gastric cancer patients develop cachexia, patients are unlikely to obtain clinically significant benefits from conventional treatment. Therefore, it is important to find biomarkers for early detection of cachexia. The investigators carried out a plasma-derived exosomal microRNA(miRNA) study for early diagnosis of cachexia in gastric cancer, and the development of early diagnosis kits for gastric cancer cachexia.

Conditions

Interventions

TypeNameDescription
OTHERcachexiaCachexia mainly manifests as weight loss. 1)weight loss \>5% over past 6 months. 2)BMI\<20 and any degree of weight loss \>2%. 3)Appendicular skeletal muscle index consistent with sarcopenia and any degree of weight loss \>2%.

Timeline

Start date
2021-06-01
Primary completion
2024-09-01
Completion
2024-09-01
First posted
2024-02-26
Last updated
2024-02-26

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06277986. Inclusion in this directory is not an endorsement.